Sera Prognostics Inc (SERA)

Currency in USD
2.56
-0.04(-1.35%)
Real-time Data·
SERA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected tomorrow
Fair Value
Day's Range
2.562.60
52 wk Range
1.379.13
Key Statistics
Prev. Close
2.59
Open
2.6
Day's Range
2.56-2.6
52 wk Range
1.37-9.13
Volume
4.67K
Average Volume (3m)
392.32K
1-Year Change
-68.1%
Book Value / Share
2.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SERA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.00
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Sera Prognostics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Sera Prognostics Inc Company Profile

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS beat expectations at -$0.20 vs -$0.27 forecast, despite revenue miss of $38,000 vs $200,000 expected
  • Stock rose 4.17% in aftermarket trading to $2.50, reflecting investor optimism despite revenue shortfall
  • Company maintains strong balance sheet with $114.2M cash, focuses on Medicaid expansion and geographic growth
  • 2025 viewed as foundational year for commercialization, preparing for potential clinical guideline updates in 2026-2028
  • CEO emphasizes cost-saving potential of preterm birth risk test, targeting $4,000 per day savings in NICU expenses
Last Updated: 07/05/2025, 22:48
Read Full Transcript

Compare SERA to Peers and Sector

Metrics to compare
SERA
Peers
Sector
Relationship
P/E Ratio
−3.0x−1.7x−0.5x
PEG Ratio
−0.22−0.030.00
Price/Book
1.0x4.3x2.6x
Price / LTM Sales
848.5x37.4x3.3x
Upside (Analyst Target)
-285.7%43.5%
Fair Value Upside
Unlock25.0%6.3%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.20 / -0.27
Revenue / Forecast
38.00K / 200.00K
EPS Revisions
Last 90 days

SERA Income Statement

People Also Watch

163.43
CRCL
-0.85%
2.66
INMB
-6.88%
7.520
CAPR
-2.08%
0.3699
VXRT
+3.96%
1.93
NXTT
+1.05%

FAQ

What Stock Exchange Does Sera Prognostics Trade On?

Sera Prognostics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sera Prognostics?

The stock symbol for Sera Prognostics is "SERA."

What Is the Sera Prognostics Market Cap?

As of today, Sera Prognostics market cap is 96.44M.

What Is Sera Prognostics's Earnings Per Share (TTM)?

The Sera Prognostics EPS (TTM) is -0.93.

When Is the Next Sera Prognostics Earnings Date?

Sera Prognostics will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is SERA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sera Prognostics Stock Split?

Sera Prognostics has split 0 times.

How Many Employees Does Sera Prognostics Have?

Sera Prognostics has 64 employees.

What is the current trading status of Sera Prognostics (SERA)?

As of 05 Aug 2025, Sera Prognostics (SERA) is trading at a price of 2.56, with a previous close of 2.59. The stock has fluctuated within a day range of 2.56 to 2.60, while its 52-week range spans from 1.37 to 9.13.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.